CONTEXT
haplo-SCT, neuroblastoma, Toxicity
DISEASE, GRAFT-VERSUS-HOST DISEASE, NEUROBLASTOMA, REMISSIONS


Survival rates for patients with relapsed high-risk neuroblastoma are poor. This study examined feasibility, safety, and response to an immunotherapeutic regimen of dinutuximab beta and low-dose subcutaneous interleukin-2 after haploidentical stem-cell transplantation (haplo-SCT) in patients with relapsed high-risk neuroblastoma.
Five-year event-free survival and overall survival from start of trial treatment were 43% and 53%, respectively. Overall response rate and complete response rate in 43 patients with evidence of disease after haplo-SCT were 51% and 35%, respectively. Toxicity profile and treatment-related mortality of the combinational treatment were favorable with a low frequency of graft-versus-host disease.
Immunotherapy with dinutuximab beta after haplo-SCT is feasible, safe, and results in long-term remissions. These findings inform the next steps that include definitive randomized trials to determine the role of the individual components of the therapeutic regimens.**Relevance section written by The anti-GD2 antibody dinutuximab beta (ch14.18/CHO; DB) is approved as frontline postconsolidation therapy in HR-NB.